Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study.Luca Gianni, Giuseppe Viale, Marco Colleoni et al.|Journal of Clinical Oncology|2019Cited by 7
CRISTALLO: Results from a Phase III Trial of Venetoclax-Obinutuzumab Versus Fludarabine, Cyclophosphamide and Rituximab or Bendamustine-Rituximab in Patients with Untreated Chronic Lymphocytic Leukemia without Del(17p) or <i>TP53</i> MutationsJeff P. Sharman, Franck Morschhauser, Stephen Opat et al.|Blood|2024Cited by 3
Reduction of Tumor Lysis Syndrome Risk after Debulking with Obinutuzumab in Patients Treated with Venetoclax-Obinutuzumab in the Randomized Phase 3 CRISTALLO TrialPaolo Sportoletti, Jeff P. Sharman, Luca Laurenti et al.|Blood|2024Cited by 0